The University of Connecticut

School of Pharmacy

Presents the

**Henry A. Palmer C.E. FINALE 2023**

A LIVE (both virtual and in-person) application and knowledge-based continuing education activity for practicing pharmacists in all settings



**Friday, December 15, 2023**

**7:30 am-5:00 pm Eastern Time
Sheraton Hartford South**

**Rocky Hill, CT**

This activity allows pharmacists to select from a wide array of continuing education activities, including sessions designated as law (2 sessions), immunization (1 session) and patient safety (1 session). Participants may select from one to eight hours, choosing topics that best meet their needs.

*7:30-8:00 a.m*. - **Registration and Check-In/Sign-In**

*8:00-8:05 a.m.* - **Opening Remarks-** Philip Hritcko, Dean, School of Pharmacy

*8:05-8:10 a.m.* – **Operational Instructions**-Jeannette Y. Wick, Dir. OPPD

**8:10-9:10 a.m. –** **LAW: Off-Label Drug Use and The Pharmacist’s Role**

 Jennifer A. Osowiecki, RPh, JD, Cox & Osowiecki, LLC, Hartford, CT

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. Define the term “off-label” in terms of drug promotion, prescribing, and use. 2. Distinguish between the use of unapproved drugs and unapproved uses of approved drugs. 3. List at least two reasons why off-label drug promotion could be harmful to patients. 4. Explain whether a pharmacist has an obligation to dispense (or not dispense) a drug prescribed for an off-label use. 5. Identify potential liabilities for pharmacists who recommend off-label use of a drug.  |

0009-0000-23-037-L03-P (0.1 CEU or 1 contact hour) (application-based)

**9:15-10:15 a.m. – The ABCD of Off-Label Medications for Weight Management**

*Devra Dang, PharmD, CDCES, FNAP, Associate Clinical Professor, UConn School of Pharmacy, Storrs, CT*

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. Discuss the main principles of management of adiposity-based chronic disease (ABCD)
2. Identify the efficacy of commonly prescribed medications that may be used off-label for weight reduction
3. List major safety considerations for medications prescribed off-label for weight reduction
 |

 0009-0000-23-038-L01-P (0.1 CEU or 1 contact hour) (Knowledge-based)

**10:20-11:20 a.m. TOP 10 Cardiovascular Drugs Used Off Label!!!**

*C. Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy* *Practice University of Connecticut School of Pharmacy, Storrs, CT*

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. Identify how an FDA approved and off label indication differ and the implications of that differential designation
2. Identify which 10 FDA approved cardiovascular drugs have the most promising off label uses for treating other cardiac or noncardiac disorders
3. Describe the mechanisms of action for the purported off label uses of these drugs
4. Identify which national guidelines or consensus statements recommend the off-label use of drugs
 |

0009-0000-23-039-L01-P (0.1 CEU or 1 contact hour) (Application-based)

**11:25-12:25 p.m. – Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause**

 *Kelsey Giara, PharmD, Freelance Medical Writer, Pelham, NH*

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. Recognize diverse instances of off-label drug use in women's health, spanning pre-conception

to menopause1. Discuss risks and advantages associated with off-label drug utilization during

various reproductive stages1. Identify the pharmacist's role in advocating for safe and informed off-label drug use

for women’s health |

0009-0000-23-040-L01-P (0.1 CEU or 1 contact hour (Application-based)

**12:25-12:45 p.m. – BREAK-light snacks will be served.**

**12:45-1:45 p.m. –****Law: Braving Buprenorphine (BUP): Exploring Off Label Use of Products for Pain Management and Opioid Use Disorder (OUD)**
*Megan Mitchell, PharmD,MS, Clinical Pharmacy Specialist in Palliative Care and Pain Management, University of Kentucky Healthcare, Lexington, KY*

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. Review the unique pharmacology of buprenorphine (BUP) including opioid receptor activity and binding affinity
2. Differentiate between the FDA approved buprenorphine products and their indications
3. Identify a comprehensive plan for safe and efficacious use of buprenorphine products for pain and opioid use disorder (OUD)
4. Recognize utility of prescribing off label use of buprenorphine products and legislature changes that supports such practice
 |

0009-0000-23-041-L03-P (0.1 CEU or 1 contact hour) (Application-based)

**1:50-2:50 p.m. - Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling**

*Jeffery Aeschlimann, PharmD, Associate Clinical Professor-Infectious Disease Specialty, University of Connecticut School of Pharmacy, Storrs, CT*

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. Compare and contrast the roles & activities of the Center for Biologics Evaluations and Research (CBER), US Food & Drug Administration (FDA), Centers for Disease Control & Prevention (CDC), and the Advisory Committee on Immunization Practices (ACIP) during the development and clinical use of vaccines in the United States.
2. Describe one specific example where the routine clinical use of a vaccine may differ from FDA-approved product prescribing information due to the following:
	1. costs
	2. disease epidemiology
	3. public acceptance
	4. vaccine supplies
 |

0009-0000-23-042-L06-P (0.1 CEU or 1 contact hour) (Application-based)

**2:55-3:55 p.m. – Antipsychotic Utilization in a Pediatric Population**

*Megan Ehret, PharmD, MS, BCPP, Professor, Co-Director* of Mental Health Program *, University of Maryland School of Pharmacy, Baltimore, MD*

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. Describe current practice guidelines the use of antipsychotic medications in a pediatric population.
2. Outline adverse effects associated with the use of antipsychotic medication in a pediatric population.
3. Discuss when to initiate an antipsychotic medication in a pediatric patient.
 |

0009-0000-23-043-L01-P (0.1 CEU or 1 contact hour) (Knowledge-based)

**4:00-5:00 p.m. – Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control** *Jeannette Y. Wick, RPh, MBA, Director Office of Professional Pharmacy Development, UConn School of Pharmacy, Storrs, CT*

|  |
| --- |
| At the conclusion of this presentation, **pharmacists** will be able to: |
| 1. LIST the numerous off label uses of gabapentin and trazodone.
2. DESCRIBE which of those uses are supported by actual evidence
3. INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience
4. ARTICULATE ways to approach prescribers with alternative suggestions
 |

 0009-0000-23-044-L05-P (0.1 CEU or 1 contact hour) (Knowledge-based)

**CE FINALE ENCORE WEBINARS AVAILABLE**

If you find you cannot make it to our LIVE EVENT on Friday, December 15th, you can participate in our 7 ENCORE LIVE WEBINARS that will be streamed on the following dates:

* Monday, December 18, 12:00 (Noon) - 1:00 pm – **TOP 10 Cardiovascular Drugs Used Off Label!!!**
* Monday, December 18, 7:00 pm - 8:00 pm – **Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause**
* Tuesday, December 19, 12:00 (Noon) - 1:00 pm - **Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling**
* Tuesday, December 19, 7:00 pm-8:00 pm – **Antipsychotic Utilization in a Pediatric Population**
* Tuesday, December 19, 8:10 pm – 9:10 pm - **The ABCD of Off-Label Medications for Weight Management**
* Wednesday, December 20, 12:00 pm-1:00 pm – **Law: LAW: Off-Label Drug Use and The Pharmacist’s Role**
* Wednesday, December 20, 7:00 pm - 8:00 pm – **Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control**

**Registration Information**

Online: <https://ce.pharmacy.uconn.edu/henry-a-palmer-ce-finale/>

**A continuous class schedule format will be used. This format does not include breaks but does include a 20 minute lunch period.**

**Refunds and Cancellations:** The registration fee, less a $60 processing fee, is refundable for those who cancel their registration three (3) days prior to the program (by December 12) After that time, no refund is available.

**Location:** The Henry A. Palmer C.E. Finale will be held both virtually or in-person. You must sign in to the Webex link at the designated time using the link in your confirmation email if you decide to participate virtually.

**Continuing Education Units**

 The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 8 contact hours (0.80 CEU) two of which are law credits, and one is an Immunization Credit and one is a Patient Safety Credit.

**Please Note**: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (January 31, 2024). Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with joanne.nault@uconn.edu to resolve a discrepancy in a timely manner. **PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to assure that your credits have been properly uploaded. Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.**

**Activity Support: There is no funding for this program.**

**Registration Form – ONLINE PLEASE, our check processing process is quite slow.**

Henry A. Palmer C.E. Finale 2023 - December 15, 2023 and CE Finale Encore Webinars December 18-20, 2023. Registration AFTER December 12, will incur a $25 late fee.

Name \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Email: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DOB: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Bus/Home Phone \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_NABP e-profile ID \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Company/Organization \_

**Event Registration Information:**

**Please register me for the sessions/times as checked below:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Time | Topics | CEUs | Time | Topics | CEUs |
|  8:10–9:10 | Law  | 0.1 |  12:45–1:45 | Law:BUP | 0.1 |
|  9:15–10:15 | Weight Mgmt | 0.1 |  1:50–2:50 | Immunization | 0.1 |
|  10:20–11:20 | Off label CV drugs  | 0.1 |  2:55–3:55 | Pediatric Psych | 0.1 |
| \_\_\_\_11:25–12:25 | Women’s Health | 0.1 |  4:00–5:00 | Gabapentin | 0.1 |

**Registration Fees: 50% discount for UConn faculty/preceptors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| One Hour | (0.1 CEUs) | $60.00 | Five Hours | (0.5 CEUs) | $120.00 |
| Two Hours | (0.2 CEUs) | $75.00 | Six Hours | (0.6 CEUs) | $135.00 |
| Three Hours | (0.3 CEUs) | $90.00 | Seven Hours | (0.7 CEUs) | $150.00 |
| Four Hours | (0.4 CEUs) | $105.00 | Eight Hours | (0.8 CEUs) | $165.00 |

Please note with our new online registration for CE Finale and electronic distribution of your statement of credit to CPE Monitor, you MUST attend the sessions for which you registered.  If for some reason you attend different activities, you MUST notify us. Otherwise you will not be able to access the system or receive appropriate credit for your continuing education.

*Fees will be calculated for total hours.*

Total Amount Due \_\_\_\_\_\_\_\_\_

**Encore Webinar Registration Information (Dec 18-20, 2023):**

Online: https://ce.pharmacy.uconn.edu/henry-a-palmer-ce-finale/ Or by mail using the registration form below.

Law: Off Label Drugs \_\_\_\_\_ Law-BUP \_\_\_\_\_

Weight Mgmt \_\_\_\_\_ Immunization \_\_\_\_\_

CV Drugs off label \_\_\_\_\_ Ped Psych \_\_\_\_\_

Women’s Health \_\_\_\_\_ Pt. Safety: Gabapentin \_\_\_\_\_

# Webinars \_\_\_\_\_\_ x $25 = $\_\_\_\_\_\_\_\_Amount Due

|  |  |  |
| --- | --- | --- |
| **Remit check payment to:**Remit payment to:UConn School of Pharmacy – Attn: Joanne Nault69 N. Eagleville Road Unit 3092Storrs, CT 06269**PLEASE REGISTER ON-LINE IF AT ALL POSSIBLE, OUR CHECK PROCESSING IS SLOW.** |  |  MasterCard  Visa  Discover  Amex*If paying by credit card, charges will appear as UConn on your credit card statement.*\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Credit Card Number Exp. Date (MM/YY) Security Code\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Name Exactly as it Appears on Card \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Credit Card Billing Address \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_City State Zip  |